Literature DB >> 23872792

Hoxb8 regulates expression of microRNAs to control cell death and differentiation.

M Salmanidis1, G Brumatti, N Narayan, B D Green, J A van den Bergen, J J Sandow, A G Bert, N Silke, R Sladic, H Puthalakath, L Rohrbeck, T Okamoto, P Bouillet, M J Herold, G J Goodall, A M Jabbour, P G Ekert.   

Abstract

Hoxb8 overexpression immortalises haematopoietic progenitor cells in a growth-factor-dependant manner and co-operates with interleukin-3 (IL-3) to cause acute myeloid leukaemia. To further understand how Hoxb8 contributes to myeloid cell immortalisation, we generated IL-3-dependant myeloid cells expressing Hoxb8 under the control of an inducible promoter. Downregulation of Hoxb8, in the presence of IL-3, caused cell-cycle arrest and apoptosis in the majority of cells. Apoptosis was dependant on Bax and Bak and, in part, on Bim, which was repressed by Hoxb8. Deletion of the miR-17∼92 seed sequences in the Bim 3'UTR abolished Hoxb8-dependant regulation of Bim reporter constructs. Expression of all six miRNAs from this cluster were elevated when Hoxb8 was overexpressed. The miR-17∼92 cluster was required for repression of Bim in Hoxb8-immortalised cells and deletion of the miR-17∼92 cluster substantially inhibited Hoxb8, but not Hoxa9, mediated survival and proliferation. Hoxb8 appears to promote miR-17∼92 expression through c-Myc, a known transcriptional regulator of the miR-17∼92 cluster. We have uncovered a previously unrecognised link between Hoxb8 expression and microRNAs that provides a new insight into the oncogenic functions of Hoxb8.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23872792      PMCID: PMC3770316          DOI: 10.1038/cdd.2013.92

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  50 in total

1.  Puma indirectly activates Bax to cause apoptosis in the absence of Bid or Bim.

Authors:  A M Jabbour; J E Heraud; C P Daunt; T Kaufmann; J Sandow; L A O'Reilly; B A Callus; A Lopez; A Strasser; D L Vaux; P G Ekert
Journal:  Cell Death Differ       Date:  2008-12-12       Impact factor: 15.828

2.  Trithorax, Hox, and TALE-class homeodomain proteins ensure cell survival through repression of the BH3-only gene egl-1.

Authors:  Malia B Potts; David P Wang; Scott Cameron
Journal:  Dev Biol       Date:  2009-02-28       Impact factor: 3.582

3.  Myeloid progenitor cells lacking p53 exhibit delayed up-regulation of Puma and prolonged survival after cytokine deprivation.

Authors:  Anissa M Jabbour; Carmel P Daunt; Benjamin D Green; Sandra Vogel; Lavinia Gordon; Rachel S Lee; Natasha Silke; Richard B Pearson; Cassandra J Vandenberg; Priscilla N Kelly; Stephen L Nutt; Andreas Strasser; Christoph Borner; Paul G Ekert
Journal:  Blood       Date:  2009-11-17       Impact factor: 22.113

4.  AbdB-like Hox proteins stabilize DNA binding by the Meis1 homeodomain proteins.

Authors:  W F Shen; J C Montgomery; S Rozenfeld; J J Moskow; H J Lawrence; A M Buchberg; C Largman
Journal:  Mol Cell Biol       Date:  1997-11       Impact factor: 4.272

5.  c-Jun N-terminal kinase/c-Jun inhibits fibroblast proliferation by negatively regulating the levels of stathmin/oncoprotein 18.

Authors:  Yvonne Y C Yeap; Ivan H W Ng; Bahareh Badrian; Tuong-Vi Nguyen; Yan Y Yip; Amardeep S Dhillon; Steven E Mutsaers; John Silke; Marie A Bogoyevitch; Dominic C H Ng
Journal:  Biochem J       Date:  2010-09-01       Impact factor: 3.857

6.  The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression.

Authors:  Piu Wong; Masayuki Iwasaki; Tim C P Somervaille; Francesca Ficara; Christine Carico; Christopher Arnold; Chang-Zheng Chen; Michael L Cleary
Journal:  Cancer Res       Date:  2010-04-20       Impact factor: 12.701

7.  miR-19 is a key oncogenic component of mir-17-92.

Authors:  Virginie Olive; Margaux J Bennett; James C Walker; Cong Ma; Iris Jiang; Carlos Cordon-Cardo; Qi-Jing Li; Scott W Lowe; Gregory J Hannon; Lin He
Journal:  Genes Dev       Date:  2009-12-15       Impact factor: 11.361

8.  HOXA9 is required for survival in human MLL-rearranged acute leukemias.

Authors:  Joerg Faber; Andrei V Krivtsov; Matthew C Stubbs; Renee Wright; Tina N Davis; Marry van den Heuvel-Eibrink; Christian M Zwaan; Andrew L Kung; Scott A Armstrong
Journal:  Blood       Date:  2008-12-03       Impact factor: 22.113

9.  MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes.

Authors:  Mika Inomata; Hiroyuki Tagawa; Yong-Mei Guo; Yoshihiro Kameoka; Naoto Takahashi; Kenichi Sawada
Journal:  Blood       Date:  2008-10-21       Impact factor: 22.113

10.  MiR-17-92 cluster is associated with 13q gain and c-myc expression during colorectal adenoma to adenocarcinoma progression.

Authors:  B Diosdado; M A van de Wiel; J S Terhaar Sive Droste; S Mongera; C Postma; W J H J Meijerink; B Carvalho; G A Meijer
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

View more
  14 in total

1.  Functionally distinct roles for different miR-155 expression levels through contrasting effects on gene expression, in acute myeloid leukaemia.

Authors:  N Narayan; L Morenos; B Phipson; S N Willis; G Brumatti; S Eggers; N Lalaoui; L M Brown; H J Kosasih; R C Bartolo; L Zhou; D Catchpoole; R Saffery; A Oshlack; G J Goodall; P G Ekert
Journal:  Leukemia       Date:  2016-10-14       Impact factor: 11.528

2.  Role of miR-196 and its target gene HoxB8 in the development and proliferation of human colorectal cancer and the impact of neoadjuvant chemotherapy with FOLFOX4 on their expression.

Authors:  Songfei Shen; Jie Pan; Xingrong Lu; Pan Chi
Journal:  Oncol Lett       Date:  2016-09-29       Impact factor: 2.967

3.  Ssb1 and Ssb2 cooperate to regulate mouse hematopoietic stem and progenitor cells by resolving replicative stress.

Authors:  Wei Shi; Therese Vu; Didier Boucher; Anna Biernacka; Jules Nde; Raj K Pandita; Jasmin Straube; Glen M Boyle; Fares Al-Ejeh; Purba Nag; Jessie Jeffery; Janelle L Harris; Amanda L Bain; Marta Grzelak; Magdalena Skrzypczak; Abhishek Mitra; Norbert Dojer; Nicola Crosetto; Nicole Cloonan; Olivier J Becherel; John Finnie; Jeffrey R Skaar; Carl R Walkley; Tej K Pandita; Maga Rowicka; Krzysztof Ginalski; Steven W Lane; Kum Kum Khanna
Journal:  Blood       Date:  2017-03-07       Impact factor: 22.113

4.  Low expression of microRNA-1908 predicts a poor prognosis for patients with ovarian cancer.

Authors:  Changcai Teng; Hong Zheng
Journal:  Oncol Lett       Date:  2017-08-03       Impact factor: 2.967

5.  HOXB8 promotes tumor metastasis and the epithelial-mesenchymal transition via ZEB2 targets in gastric cancer.

Authors:  Wen-Jin Ding; Min Zhou; Mei-Mei Chen; Chun-Ying Qu
Journal:  J Cancer Res Clin Oncol       Date:  2016-10-19       Impact factor: 4.553

Review 6.  Regulation of Bim in Health and Disease.

Authors:  Ronit Vogt Sionov; Spiros A Vlahopoulos; Zvi Granot
Journal:  Oncotarget       Date:  2015-09-15

7.  HoxA9 regulated Bcl-2 expression mediates survival of myeloid progenitors and the severity of HoxA9-dependent leukemia.

Authors:  Gabriela Brumatti; Marika Salmanidis; Chung H Kok; Rebecca A Bilardi; Jarrod J Sandow; Natasha Silke; Kylie Mason; Jolanda Visser; Anissa M Jabbour; Stefan P Glaser; Toru Okamoto; Philippe Bouillet; Richard J D'Andrea; Paul G Ekert
Journal:  Oncotarget       Date:  2013-11

8.  In-vivo fusion of human cancer and hamster stromal cells permanently transduces and transcribes human DNA.

Authors:  David M Goldenberg; Robert J Rooney; Meiyu Loo; Donglin Liu; Chien-Hsing Chang
Journal:  PLoS One       Date:  2014-09-26       Impact factor: 3.240

Review 9.  MicroRNA-regulated pathways in hematological malignancies: how to avoid cells playing out of tune.

Authors:  Alessandro Fatica; Francesco Fazi
Journal:  Int J Mol Sci       Date:  2013-10-18       Impact factor: 5.923

10.  Synergistic signaling of KRAS and thyroid hormone receptor β mutants promotes undifferentiated thyroid cancer through MYC up-regulation.

Authors:  Xuguang Zhu; Li Zhao; Jeong Won Park; Mark C Willingham; Sheue-Yann Cheng
Journal:  Neoplasia       Date:  2014-09       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.